Bristol-Myers Squibb and AstraZeneca receive advertising authorisation for ONGLYZA in Europe Bristol-Myers Squibb Organization and AstraZeneca announced today that the European Commission has granted marketing authorisation for ONGLYZATM in the 27 countries of the European Union http://priligy-sverige.com read more . ONGLYZA is definitely indicated as a once-daily 5 mg oral tablet dosage in adult patients with type 2 diabetes mellitus to boost glycaemic control: in combination with metformin, when metformin by itself, with diet and exercise, does not provide adequate glycaemic control; in conjunction with a sulphonylurea, when sulphonylurea by itself, with exercise and diet, does not provide sufficient glycaemic control in individuals for whom usage of metformin is considered inappropriate; or in conjunction with a thiazolidinedione, when the thiazolidinedione by itself, with exercise and diet, does not provide sufficient glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate.
The pharmacological benefits of covalent drugs are discussed including the potential to address the problem of drug-level of resistance mutations that often arise in malignancy and in infectious diseases. Predicated on this review article, it is obvious that structural bioinformatics approaches, in conjunction with structure-based drug design, may enable the engineering of highly selective covalent medicines and a resurgence of curiosity in this important class of therapeutics.. Wide opportunities for covalent drugs Avila scientists publish ‘The Resurgence of Covalent Drugs’ in Nature Reviews Drug Discovery; publication recognizes the potential of rational covalent drug design to expand the breadth of therapeutic usage of targeted covalent medicines Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, today announced the publication of a scientific review article in Nature Reviews Drug Discovery titled ‘The Resurgence of Covalent Drugs’ .